> ## Content Index
> Fetch the complete content index at: https://www.bullished.co/llms.txt
> Use this file to discover other available public pages before exploring further.

# Rigel Earns $13.2 Million As Costs Climb To $63.8 Million Despite Higher Drug Sales
- URL: https://www.bullished.co/rigel-earns-13-2-million-as-costs-climb-to-63-8-million-despite-higher-drug-sales-7c26995f/
- Published: 2026-11-06T14:26:41.000Z
- Updated: 2026-11-06T14:26:41.000Z
- Description: Veppanu brought in $6.6 million in initial sales, while Rigel narrowed its annual revenue outlook, which excludes the breast-cancer drug.
- Author: Matteo Parrino
- Tags: SEC Filings, RIGL, Industry: Healthcare

[Rigel Pharmaceuticals](https://www.bullished.co/tag/rigl/), which develops and sells drugs for blood disorders and cancer, reported third-quarter net income of [$13.2 million](https://www.sec.gov/Archives/edgar/data/0001034842/000103484226000062/rigl-20261105.htm?ref=bullished.co) Thursday, down from $27.9 million a year earlier, in results accompanying its SEC filing. Drug sales rose 13%, but costs climbed to $63.8 million from $41.0 million as the company spent more on clinical development and its breast-cancer drug launch.

## Development And Launch Costs Climb

Revenue totaled $80.9 million, including $72.3 million from product sales and $8.6 million from collaborations. Diluted earnings fell to $0.65 per share from $1.46 a year earlier.

Rigel attributed the expense increase mainly to its R289 and vepdegestrant clinical programs, product costs, personnel and commercial spending for vepdegestrant, sold as Veppanu. Pretax income fell to $17.4 million from $27.6 million.

The first nine months show a similar split between sales and earnings. Product sales reached $194.2 million, up 17%, while total revenue was $218.4 million against $224.5 million a year earlier. The earlier period included $40.0 million of non-cash collaboration revenue from the release of a remaining cost-sharing liability under Rigel’s agreement with Eli Lilly, plus a $3.0 million milestone for Tavalisse’s approval in the Republic of Korea.

Nine-month net income was $39.1 million, or $1.97 per diluted share, compared with $99.0 million, or $5.38 per diluted share. Expenses rose to $165.8 million from $122.2 million. Cash, cash equivalents and short-term investments stood at $99.3 million on September 30, versus $155.0 million on December 31, 2025.

## Veppanu Adds A Breast-Cancer Business

Veppanu generated [$6.6 million](https://www.sec.gov/Archives/edgar/data/0001034842/000103484226000062/rigl-20261105xex991q32026r.htm?ref=bullished.co) in initial net sales after becoming commercially available in the U.S. on August 13, 2026\. The FDA-approved drug treats adults with advanced or metastatic breast cancer that is estrogen receptor-positive, HER2-negative and carries an ESR1 mutation detected by an authorized test, after progression on at least one endocrine treatment.

Raul Rodriguez, Rigel’s president and CEO, said: “In the first six weeks of launch we shipped VEPPANU to more than 100 patients and clinics and have already seen [many refills](https://www.sec.gov/Archives/edgar/data/0001034842/000103484226000062/rigl-20261105xex991q32026r.htm?ref=bullished.co).”

The launch adds to a portfolio built around Tavalisse for chronic immune thrombocytopenia, a disorder in which the immune system destroys platelets; Rezlidhia for certain cases of acute myeloid leukemia; and Gavreto for certain lung and thyroid cancers.

Tavalisse remained the largest sales contributor in the quarter at $46.0 million, up 3% from $44.7 million. Rezlidhia brought in $9.9 million, up 20% from $8.3 million, while Gavreto fell 11% to $9.8 million from $11.1 million.

For the first nine months, Tavalisse sales rose 15% to $130.6 million and Rezlidhia rose 25% to $26.9 million. Gavreto sales fell 6% to $30.1 million. Outside the U.S., partner Knight Therapeutics received Colombian regulatory approval for Tavalisse in September and launched it in Brazil in October.

## A Narrower Outlook, Excluding Veppanu

Rigel now expects approximately $290 to $295 million in 2026 revenue, excluding Veppanu, compared with approximately $285 to $295 million previously. The revision raises the bottom of the total revenue range while lowering the ceiling for product sales.

The outlook includes approximately $255 to $260 million in product sales, previously approximately $255 to $265 million, and approximately $35 million from collaborations, previously approximately $30 million. Rigel still expects positive full-year net income while funding existing and new clinical programs.

R289, an investigational drug not approved by the FDA, is in an early-stage study for relapsed or treatment-resistant lower-risk myelodysplastic syndrome. Rigel expects to finish enrollment and select a dose for further development by year-end. Updated results, including initial efficacy findings from the study’s dose-expansion portion, are scheduled for an oral presentation at the American Society of Hematology meeting in December.

The December meeting will also include three poster presentations on fostamatinib, the drug sold as Tavalisse, in immune thrombocytopenia and warm autoimmune hemolytic anemia.

Learn

- [Item 2.02: results of operations →](https://www.bullished.co/learn/8-k-items-explained/#item-202-results-of-operations)  
From 8-K Items Explained: What Every Item Code From 1.01 To 9.01 Tells You, With Examples

### Sources

- [8-K Filing — RIGEL PHARMACEUTICALS INC (RIGL)](https://www.sec.gov/Archives/edgar/data/0001034842/000103484226000062/rigl-20261105.htm?ref=bullished.co) — SEC EDGAR
- [Exhibit rigl-20261105xex991q32026r.htm — RIGEL PHARMACEUTICALS INC 8-K exhibit](https://www.sec.gov/Archives/edgar/data/0001034842/000103484226000062/rigl-20261105xex991q32026r.htm?ref=bullished.co) — SEC EDGAR
- [Rigel outlines $290M-$295M 2026 revenue outlook as VEPPANU launch starts with $6.6M sales (NASDAQ:RIGL) | Seeking Alpha](https://seekingalpha.com/news/4667741-rigel-outlines-290m-295m-2026-revenue-outlook-as-veppanu-launch-starts-with-6%5F6m-sales?ref=bullished.co) — seekingalpha.com
- [Rigel Reports Third Quarter 2026 Financial Results](https://finance.yahoo.com/healthcare/articles/rigel-reports-third-quarter-2026-210100974.html?ref=bullished.co) — Yahoo Finance
- [Rigel Announces Oral Presentation of Phase 1b Data for R289 in Patients with Lower-Risk MDS at the 68th American Society of Hematology Annual Meeting and Exposition – Company Announcement - FT.com](https://markets.ft.com/data/announce/detail?dockey=600-202611040915PR%5FNEWS%5FUSPRX%5F%5F%5F%5FSF88539-1&ref=bullished.co) — Financial Times

### More on Rigel Pharmaceuticals

- [Rigel Says Most Of Vepinu's $6.6 Million Launch Was Real Demand, Not Stocking](https://www.bullished.co/rigel-says-most-of-vepinus-6-6-million-launch-was-real-demand-not-stocking-084bb37a/)

[All Rigel Pharmaceuticals (RIGL) coverage →](https://www.bullished.co/tag/rigl/)